Fundraising FoxSR One Capital Management — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsQuan CapitalRA CapitalWellington ManagementWestRiver Group
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Co-investorsBain Capital Life SciencesOrbiMedLilly Asia VenturesT. Rowe PriceAscenta CapitalTCG Crossover+3 more
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Board seatRajeev Dadoo· per SEC Form D
Co-investorsNextech InvestOrbiMedRA CapitalSofinnova Ventures
Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs.
BiotechHealthtechSan Diego, US
Neil Gibson(Executive Officer)Kleanthis Xanthopoulos(Executive Officer, Director)
BoardB. Lynne Parshall(Director)Mark G. Foletta(Director)John Maraganore(Director)Douglas E. Williams(Director)
Board seatJake Nunn· per SEC Form D · $34.6M raise · filed Dec 2021
Co-investorsForesite CapitalNew Enterprise Associates (NEA)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.